Concurrent use of Sr-89 chloride with bone-modifying agent(denosumab, zoledronic acid) is safe and effective for breast cancer patients with painful bone metastases
Not Applicable
- Conditions
- breast cancer
- Registration Number
- JPRN-UMIN000014269
- Lead Sponsor
- St. Marianna University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
1. a case indicated chemotherapy 2. a case that has other cancer 3. a case that has grave complication 4. a case that has grave bone marrow suppression 5. a case that has grave renal dysfunction 6. a case that has invasive dental treatment 7. a woman that is pregnant, breast-feed and may be pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence rates of myelotoxicity and hypocalcemia after fourth time uses of bone-modifying agent after use of Sr-89.
- Secondary Outcome Measures
Name Time Method efficacy assessment to evaluated numerical rating scale, analgesic drug dosages, time to SRE, BAP or ALP, tumor marker, bone scintigraphy